Companies are outsourcing more business to third-party logistics providers (3PLs), and that rising trend drove larger industrial leases in 2025, with 3PLs capturing the largest share of the top 100 leases, according to a report from commercial real estate firm CBRE.3PLs accounted for 44 of the...
Microsoft on Monday issued out-of-band security patches for a high-severity Microsoft Office zero-day vulnerability exploited in attacks. The vulnerability, tracked as CVE-2026-21509, carries a CVSS score of 7.8 out of 10.0. It has been described as a security feature bypass in Microsoft Office....
Cybersecurity researchers have disclosed details of a new campaign that combines ClickFix-style fake CAPTCHAs with a signed Microsoft Application Virtualization (App-V) script to distribute an information stealer called Amatera. “Instead of launching PowerShell directly, the attacker uses...
Cybersecurity teams increasingly want to move beyond looking at threats and vulnerabilities in isolation. It’s not only about what could go wrong (vulnerabilities) or who might attack (threats), but where they intersect in your actual environment to create real, exploitable exposure. Which...
Original story from Johns Hopkins Medicine (MD, USA). The first comprehensive single-cell atlas of bone-innervating sensory neurons has identified their dual role in reporting and repairing bone damage, providing a potential target for drugs that might enhance bone healing. When a house catches...
How is the biopharmaceutical sector evolving, and where are opportunities for advancement? The biopharma sector has undergone significant change over the last 30 years, and it’s set to continue seeing steady change as manufacturing logistics shift to meet patient needs and global policies. In...
Amid a rebound in SPAC activity, the prolific “crossover” investor is aiming for its third blank-check merger since 2022 following deals with Moonlake Immunotherapeutics and BridgeBio Oncology Therapeutics.
Continue reading →
The ongoing surge in licensing deals for early drug prospects should continue this year and involve more cell and gene therapies, which have had trouble securing funding in the U.S., the firm said in a new report.
Continue reading →